Alpharma Expects FDA Reinspection Of Baltimore Site In Early 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Alpharma expects an early 2005 reinspection by FDA of its liquid pharmaceuticals manufacturing plant that was the subject of an FDA-483 report earlier this year
You may also be interested in...
Alpharma Eyeing Commercial, Legal Options For Gabapentin Following ANDA Stay
The company could seek a settlement with Apotex to dismiss its challenge to Alpharma’s 180-day generic marketing exclusivity for Neurontin, the lifting of the federal appeals court stay of approval or an accelerated hearing date.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.